Literature DB >> 23010903

Unnecessary repeat Clostridium difficile PCR testing in hospitalized adults with C. difficile-negative diarrhea.

J A Nistico1, J E Hage, P E Schoch, B A Cunha.   

Abstract

The aim of this study was to determine the extent and associated costs of repeat Clostridium difficile stool polymerase chain reaction (PCR) assays in patients with initially negative PCRs. C. difficile stool PCRs were done on adult hospitalized patients with diarrhea. The number/time course of repeat PCRs on initially negative PCR patients was determined. Of 5,027 C. difficile stool PCRs, 814 (16.2 %) were positive and 4,213 (83.8 %) were negative. Ninety-seven of the initially PCR-negative patients had >2 repeat tests 1-59 days after the initial negative stool PCR. Repeat negative PCR testing rarely resulted in a subsequent positive result (0.05 %). The unnecessary costs of 97 repeat PCRs was $32,658.00. Many of these patients were originally given empiric oral anti-C. difficile therapy, in spite of repeatedly negative PCRs.

Entities:  

Mesh:

Year:  2012        PMID: 23010903     DOI: 10.1007/s10096-012-1719-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  5 in total

1.  Lack of value of repeat stool testing for Clostridium difficile toxin.

Authors:  Sowjanya S Mohan; Brian P McDermott; Subha Parchuri; Burke A Cunha
Journal:  Am J Med       Date:  2006-04       Impact factor: 4.965

2.  Vancomycin-resistant enterococci in hemodialysis patients is related to intravenous vancomycin use.

Authors:  S Fishbane; B A Cunha; S K Mittal; J Ruggian; K Shea; P E Schoch
Journal:  Infect Control Hosp Epidemiol       Date:  1999-07       Impact factor: 3.254

3.  Nonutility of repeat laboratory testing for detection of Clostridium difficile by use of PCR or enzyme immunoassay.

Authors:  Elisabeth Aichinger; Cathy D Schleck; William S Harmsen; Lisa M Nyre; Robin Patel
Journal:  J Clin Microbiol       Date:  2008-09-10       Impact factor: 5.948

4.  Detection of toxigenic Clostridium difficile in stool samples by real-time polymerase chain reaction for the diagnosis of C. difficile-associated diarrhea.

Authors:  Lance R Peterson; Rebecca U Manson; Suzanne M Paule; Donna M Hacek; Ari Robicsek; Richard B Thomson; Karen L Kaul
Journal:  Clin Infect Dis       Date:  2007-09-25       Impact factor: 9.079

5.  Identification of toxigenic Clostridium difficile by the polymerase chain reaction.

Authors:  N Kato; C Y Ou; H Kato; S L Bartley; V K Brown; V R Dowell; K Ueno
Journal:  J Clin Microbiol       Date:  1991-01       Impact factor: 5.948

  5 in total
  10 in total

1.  Reducing Unnecessary and Duplicate Ordering for Ovum and Parasite Examinations and Clostridium difficile PCR in Immunocompromised Patients by Using an Alert at the Time of Request in the Order Management System.

Authors:  Caitlin C Otto; Susan L Shuptar; Philippe Milord; Connor J Essick; Reshma Nevrekar; Svetlana L Granovsky; Susan K Seo; N Esther Babady; Steven C Martin; Yi-Wei Tang; Melissa S Pessin
Journal:  J Clin Microbiol       Date:  2015-06-10       Impact factor: 5.948

2.  Clinical characteristics of patients who test positive for Clostridium difficile by repeat PCR.

Authors:  Daniel A Green; Brie Stotler; Dana Jackman; Susan Whittier; Phyllis Della-Latta
Journal:  J Clin Microbiol       Date:  2014-08-13       Impact factor: 5.948

3.  Impact of an electronic hard-stop clinical decision support tool to limit repeat Clostridioides difficile toxin enzyme immunoassay testing on test utilization.

Authors:  Jennie H Kwon; Kimberly A Reske; Tiffany Hink; Ronald Jackups; Carey-Ann D Burnham; Erik R Dubberke
Journal:  Infect Control Hosp Epidemiol       Date:  2019-10-24       Impact factor: 3.254

Review 4.  Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories.

Authors:  Carey-Ann D Burnham; Karen C Carroll
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

Review 5.  Variations in virulence and molecular biology among emerging strains of Clostridium difficile.

Authors:  Jonathan J Hunt; Jimmy D Ballard
Journal:  Microbiol Mol Biol Rev       Date:  2013-12       Impact factor: 11.056

6.  Alerting physicians during electronic order entry effectively reduces unnecessary repeat PCR testing for Clostridium difficile.

Authors:  Robert F Luo; Suzanne Spradley; Niaz Banaei
Journal:  J Clin Microbiol       Date:  2013-08-28       Impact factor: 5.948

7.  Evaluation of the fully automated BD MAX Cdiff and Xpert C. difficile assays for direct detection of Clostridium difficile in stool specimens.

Authors:  Alexander H Dalpke; Marjeta Hofko; Markus Zorn; Stefan Zimmermann
Journal:  J Clin Microbiol       Date:  2013-03-20       Impact factor: 5.948

8.  The Role of Diagnostic Stewardship in Clostridioides difficile Testing: Challenges and Opportunities.

Authors:  Frances J Boly; Kimberly A Reske; Jennie H Kwon
Journal:  Curr Infect Dis Rep       Date:  2020-02-17       Impact factor: 3.725

9.  Diagnostic yield of repeat sampling with immunoassay, real-time PCR, and toxigenic culture for the detection of toxigenic Clostridium difficile in an epidemic and a non-epidemic setting.

Authors:  J van Prehn; C M J E Vandenbroucke-Grauls; Y H van Beurden; R van Houdt; S Vainio; C W Ang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-09-16       Impact factor: 3.267

10.  A Laboratory Medicine Best Practices Systematic Review and Meta-analysis of Nucleic Acid Amplification Tests (NAATs) and Algorithms Including NAATs for the Diagnosis of Clostridioides (Clostridium) difficile in Adults.

Authors:  Colleen S Kraft; J Scott Parrott; Nancy E Cornish; Matthew L Rubinstein; Alice S Weissfeld; Peggy McNult; Irving Nachamkin; Romney M Humphries; Thomas J Kirn; Jennifer Dien Bard; Joseph D Lutgring; Jonathan C Gullett; Cassiana E Bittencourt; Susan Benson; April M Bobenchik; Robert L Sautter; Vickie Baselski; Michel C Atlas; Elizabeth M Marlowe; Nancy S Miller; Monika Fischer; Sandra S Richter; Peter Gilligan; James W Snyder
Journal:  Clin Microbiol Rev       Date:  2019-05-29       Impact factor: 26.132

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.